Completed PHASE2 INTERVENTIONAL 1-arm NCT01568333

A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia

Sponsor: Qingdao University

Interventions Decitabine

Updated 7 times since 2017 Last updated: Aug 17, 2018 Started: Aug 31, 2015 Primary completion: Oct 31, 2017 Completion: Aug 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01568333, this PHASE2 trial focuses on Immune Thrombocytopenia and remains completed. Sponsored by Qingdao University, it has been updated 7 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Sep 2018 — Jan 2021 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Jun 2018 — Sep 2018 [monthly]

Unknown Status PHASE2

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2017 — Apr 2018 [monthly]

Recruiting PHASE2

First recorded

Aug 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Qingdao University
Shandong Provincial Hospital
Shandong University

Data source: Shandong University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jinan, China